Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review
Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review
复制标题
吉西他滨联合顺铂联合化疗治疗最初不可切除的晚期胆道癌转化手术一例报告及文献复习
DOI：
10.1007/s13691-022-00545-y
复制
发表时间：
2022
影响因子：
0.7
通讯作者：
Kawashima Yoshiyuki
中科院分区：
文献类型：
--
作者：
Miyamoto Ryoichi;Ogura Toshiro;Takahashi Amane;Ishida Hiroyuki;Matsudaira Shinichi;Amikura Katsumi;Suzuki Yuko;Shimizu Satoshi;Kihara Atsushi;Kanda Hiroaki;Kawashima Yoshiyuki
最近，描述最初不可切除的胆道癌（BTC）患者以转换手术的形式进行切除的报告数量正在增加。据报道，在不可切除的BTC患者中，与常规吉西他滨治疗相比，吉西他滨+顺铂（GC）联合治疗可显著延长中位生存时间，从8.1个月延长至11.7个月。我们报告的情况下，病人与不可切除的BTC谁经历了转换手术与GC联合治疗的部分反应。一位78岁的女性被诊断为不可切除的BTC与侵犯右肝动脉的淋巴结转移和肝转移。患者接受GC联合治疗。经过6个周期的化疗，患者获得了部分缓解。放射学检查显示原发病灶明显缩小，淋巴结和肝转移灶消失。因此，患者接受了转换手术，包括胆道切除和区域淋巴结清扫。对于术后随访，患者在未接受辅助化疗的情况下接受监测。在12个月随访期间，患者未出现复发。我们报告的情况下，病人与不可切除的BTC谁经历了转换手术与GC联合治疗的部分反应。
Recently, the number of reports describing patients with initially unresectable biliary tract cancer (BTC) who underwent resection in the form of conversion surgery is increasing. Gemcitabine plus cisplatin (GC) combination therapy has been reported to significantly prolong the median survival time from 8.1 to 11.7 months compared with conventional gemcitabine therapy in patients with unresectable BTC. We report the case of a patient with unresectable BTC who underwent conversion surgery with a partial response to GC combination therapy. A 78-year-old woman was diagnosed with unresectable BTC with invasion of the right hepatic artery by lymph node metastasis and liver metastases. The patient received GC combination therapy. After 6 cycles of chemotherapy, the patient achieved a partial response. The radiological findings revealed a marked shrinkage in the primary lesion and the disappearance of lymph node and liver metastases. Therefore, the patient underwent conversion surgery, including biliary tract resection and regional lymph node dissection. For postoperative follow-up, the patient was monitored without receiving adjuvant chemotherapy. The patient had not exhibited recurrence during the 12-month follow-up period. We report the case of a patient with unresectable BTC who underwent conversion surgery with a partial response to GC combination therapy.